Asset Details
Do you wish to reserve the book?
Advances in sleep medicine in 2019
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Advances in sleep medicine in 2019
Do you wish to request the book?
Advances in sleep medicine in 2019
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Advances in sleep medicine in 2019
2020
Overview
Based on these findings, and data from other studies in patients with obstructive sleep apnoea, the US Food and Drug Administration approved solriamfetol for excessive daytime sleepiness in patients with narcolepsy and obstructive sleep apnoea in March 2019. The obstructive sleep apnoea specific ventilatory disturbance was calculated as the area under the curve associated with obstructive events, thereby taking into account the degree, frequency, and duration of oxygen desaturation. [...]these studies in 2019 advanced our understanding of treatment of excessive daytime sleepiness, changed school start times, and improved our knowledge on the effects of obstructive sleep apnea on cognitive health, and that on neurodegeneration in RBD.
Publisher
Elsevier Ltd,Elsevier Limited
Subject
